Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Hermeyone Bell

Nurse Practitioner Houston, TX Nurse Practitioner

NPI 1316005879 CMS profile 11192278

3701 Kirby Dr, Houston, TX 77098

Open in the dashboard

General payments

$16,721

175 records reported · program years 2021–2024

Research payments

$788

Paid to them · 7 records reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Hermeyone Bell of Houston, TX is reported in the CMS Open Payments database as having received $16,721 across 175 general payments and $788 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $2,884 18
2023 General $6,060 52
2023 Research $788 7
2022 General $3,337 38
2021 General $4,441 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hermeyone Bell
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Hermeyone Bell were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Hermeyone Bell Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $4,441 $135 $40–$426 $132
2022 $3,337 $152 $48–$470 $149
2023 $6,060 $166 $54–$529 $160
2024 $2,884 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. ViiV Healthcare Company $14,064 90 payments
  2. Janssen Products, LP $873 7 payments
  3. Gilead Sciences, Inc. $844 34 payments
  4. Janssen Scientific Affairs, LLC $278 7 payments
  5. Janssen Biotech, Inc. $277 17 payments
  6. Merck Sharp & Dohme Corporation $136 7 payments
  7. Theratechnologies Inc. $115 6 payments
  8. Lilly USA, LLC $66 3 payments
  9. Hologic, LLC $22 1 payment
  10. Novo Nordisk Inc $17 1 payment
  11. Other $29 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Consulting Fee $10,145 6 payments
  2. Food and Beverage $5,252 162 payments
  3. Travel and Lodging $1,224 6 payments
  4. Education $100 1 payment
Products named General payments · program years 2021–2024
  1. DOVATO $6,503 34 payments
  2. SYMTUZA $1,285 29 payments
  3. RUKOBIA $443 7 payments
  4. CABENUVA $441 15 payments
  5. APRETUDE $404 14 payments
  6. Descovy $219 2 payments
  7. DELSTRIGO $117 6 payments
  8. EGRIFTA $115 6 payments
  9. TROGARZO $115 6 payments
  10. ISENTRESS $98 5 payments
  11. Other $356 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2024
  1. ViiV Healthcare Company $788 7 payments

Records

182 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record